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iThis review covers the period from July 2009 to June 2010,
with 3 exceptions.
Aortic Stenosis
Statin does not reduce the progression of mild-to-
moderate aortic stenosis. Two hundred sixty-nine patients
ith mild-to-moderate aortic stenosis (AS) were random-
zed to 40 mg of rosuvastatin or placebo (the ASTRONOMER
Aortic Stenosis Progression Observation: Measuring Ef-
ects of Rosuvastatin] trial) (1). At a median follow-up of
.5 years, there was no significant difference between the 2
roups in the progression of severity of AS.
atural history of “very severe” AS. Consecutive asymp-
omatic patients (age 67  16 years; women 57 years) were
followed clinically with “very severe” AS (2) defined as peak
aortic valve jet velocity (AV-Vel)5.0 m/s; aortic valve area
(AVA) was 0.63 0.12 cm2. During a median follow-up of
1 months, 96 events were observed, which included aortic
alve replacement (AVR) in 90 patients and 6 cardiac deaths
hat occurred in previously asymptomatic patients (sudden
, heart failure 4 [causes of heart failure was not given],
yocardial infarction 1). Event-free survival at 1, 2, 3, 4,
nd 6 years was 64%, 36%, 25%, 12%, and 3%, respectively.
he AVA for patients with AV-Vel 5.5 m/s and 5.0 to
.5 m/s were not statistically significantly different. Patients
ith AVA by echocardiography of 0.6 cm2 had a similar
utcome to those with AVA 0.6 cm2. Coronary artery
disease (CAD) was present in 22%; the number of patients
who had coronary arteriography was not provided.
COMMENT. This study of 116 patients, from 1995 to 2008,
was labeled as “very severe” AS.
Did these patients have “very severe” AS? The AVA
was 0.63  0.12 cm2, and the event rate at 1 and 2 years
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2011, accepted May 10, 2011.was 36% and 64%, respectively. A previous study from
the same institution of 128 patients, obtained during 1
year (1995), reported on patients with “severe” AS in
whom the AVA was 0.69  0.1 cm2 (range was 0.4 to 0.8
cm2), and the event rate at 1 and 2 years was 36% and
4%, respectively (3). Another study also reported 66
atients with “severe” AS who had no CAD on coronary
rteriography in whom the AVA was 0.61  0.17 cm2
and the event rate at 1 and 2 years was 43% and 62%,
respectively (4). Thus, there is not much difference in
AVA and event rates between patients with “very severe”
and “severe” AS. Also in this study there was no
significant difference in outcomes between those with
AVA 0.6 and 0.6 cm2, because both had severe AS.
So, what is “very severe” AS? The concept of “very severe”
AS was presented in the 2006 Denolin lecture at the
European Society of Cardiology Annual Congress (5) on
the basis of the study of Amato et al. (4) (as AVA 0.7
cm2) and that of Braunwald’s (6) “critical” obstruction to left
ventricular (LV) outflow (as aortic valve area index [AVAI]
of 0.4 cm2/m2). The AV-Vel/peak gradient by Doppler
echocardiography occurs in early systole, and the problems
are: 1) the severely stenotic aortic valve is not fully open at
that time (7); 2) even in normals (animal/human), LV
emptying in early systole is by the phenomenon of mass
acceleration (8,9), which results in an increased velocity/
gradient that is increased by sympathetic/inotropic stimu-
lation—gradients as high as 55 mm Hg have been docu-
mented (10); and 3) gradients/velocities are movable targets
(11), except with “critical AS” (also see grading severity of
AS in the following text).
Grading severity of AS is inconsistent. The grading of
333 consecutive patients who underwent cardiac catheter-
ization was evaluated (10). The criteria of mean pressure
gradient (MPG) 40 mm Hg for severe AS was inconsis-
tent with criteria of AVA calculations in 26% of the
patients. To document that a low cardiac output was not the
cause of the inconsistency, they evaluated the influence of
flow, assuming normal stroke volume of 35 ml/m2, which
s lower than the stroke volume in normal people (in whom
t is 45  10 ml/m2) (12).
COMMENT. The authors previously documented similar
inconsistencies with echocardiography/Doppler data (13).
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Year in Valvular Heart Disease September 13, 2011:1197–207These investigators have made a major contribution to
properly assessing severity of AS.
Using MPG40 mmHg as a criteria to indicate that AS
is severe, as was done in the guidelines, is the problem. In
the guidelines the Level of Evidence: C was used in 75% to
91% of the recommendations, indicating that it was based
on “opinions.” The origin and source of this criterion is
uncertain. Gradient is a per-beat function that is dependent
on LV loading conditions and contractility and also on the
pressure in the ascending aorta (AA) (11); it can frequently
be changed rapidly. In 636 patients undergoing cardiac
catheterization, MPG 50 mm Hg was specific with 90%
or more positive predictive value for severe AS (14), but
MPG 50 mm Hg had low specificity for severe AS and
was consistent with severe as well as not-severe AS. A
modification of the figure of the authors (Fig. 1) confirms
this earlier data; of interest, the majority of patients with
MPG 50 mm Hg had severe AS.
Data from 1,563 patients in the SEAS (Simvastatin and
Ezetimibe in Aortic Stenosis) study (15) from echocardio-
graphic/Doppler studies showed that pressure recovery ad-
justed AVAI (energy loss index) (16) obtained at the sinotu-
bular junction would allow “for accurate assessment of AS
severity.”
COMMENT. The best method to assess severity of AS is the
energy available to perfuse the body (Effective Energy Require-
ment), which is determined after Conservation of Energy (12).
At the present time, determination of whether AS is severe
should be based on an assessment of the combination of
Figure 1 Inconsistent Grading of
Aortic Valve Stenosis by Gradient
Relationship of mean pressure gradient (MPG) (mm Hg) to indexed aortic valve
area (cm2/m2). Data obtained by cardiac catheterization and echocardiogra-
phy/Doppler. All but 1 patient with MPG 50 mm Hg had severe aortic steno-
sis (AS), indexed aortic valve area 0.6 cm2/m2 (right panels). Those with
MPG 50 mm Hg had mild, moderate, and severe AS, although most had
severe AS. Modified and adapted, with permission, from Minners et al. (10).
New figure provided by J. Minners and C. Gohlke-Baerwolf.clinical criteria plus AVAI at cardiac catheterization/energy
loss index at the sinotubular junction by echocardiography/
Doppler of0.6 cm2/m2 and/or MPG50 mmHg (12–14),
nd determination of critical/very severe AS should be based
n AVAI of 0.4 cm2/m2 (5,6,12).
ong-term survival after AVR in very elderly persons (age
80 years) is similar to that of the general population. Of
,584 consecutive patients, 51.1% had AVR and 48.9% had
VR  coronary artery bypass graft surgery (CABG) (17).
heir actuarial survival was similar to the life expectancy of
he general population obtained from actuarial tables, which
t ages 80 to 84 years is 7 years and at age85 years is 5 years.
xtent of pre-operative myocardial fibrosis influences the
xtent of functional improvement after AVR in symp-
omatic patients with severe AS. Fifty-eight consecutive
atients with isolated symptomatic severe AS had extensive
aseline characterization before AVR that included cardiac
agnetic resonance imaging (MRI) (late-enhancement im-
ging for fibrosis) (18). Endomyocardial biopsies were
erformed intraoperatively to determine the extent of fibro-
is. The extent of histologically determined fibrosis at
aseline was similar to that determined by MRI and
orrelated with New York Heart Association (NYHA)
unctional class (FC). Nine months post-operatively, late
nhancement was unchanged. The amount of fibrosis de-
ermined the NYHA FC improvement.
COMMENT. This is an interesting and important study.
Aortic Regurgitation
Persistent diastolic dysfunction late after AVR in severe
aortic regurgitation is due to persistently increased muscle
fiber diameter, interstitial fibrosis, and fibrous content.
Eleven patients with severe aortic regurgitation (AR) were
studied before, early (21 months), and late (89 months) after
AVR with LV biplane angiograms, high-fidelity pressure
measurements, and LV endomyocardial biopsies (19). Fif-
teen healthy persons served as control subjects but did not
have endomyocardial biopsies.
In patients with AR, LV volumes and mass were in-
creased; and after AVR were reduced, LV mass decreased
but did not become normal. Left ventricular ejection frac-
tion (LVEF) was reduced and improved after AVR. Myo-
cardial fibrosis and the increased constant of muscle stiffness
were increased and remained increased late after AVR and
accounted for persistent diastolic dysfunction.
COMMENT. This is an important and valuable study.
Bicuspid Aortic Valve
Vascular dysfunction in those with dilated AA. Thirty-
two men with nonsevere AS were separated into 16
subjects (Group A) with nondilated AA (35 mm) and
those with dilated AA (n  16, Group B) and were
compared with 16 healthy men (control subjects, Group C)
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September 13, 2011:1197–207 Year in Valvular Heart Disease(20). Despite similar degrees of AS, LV mass, and function,
those in Group B had significantly higher plasma levels of
matrix metalloproteinases, higher carotid-femoral pulse wave
velocity, and blunted brachial flow-mediated vasodilatation to
hyperemia, compared with those in Group A.
Mitral Stenosis
Statins reduce progression of mitral stenosis? From an
echocardiographic database of 20 years, 315 patients who
had mitral stenosis (MS) (61  12 years of age, 71%
female) were evaluated; follow-up was 61  4 years (21).
hirty-five patients (11.1%) had been treated with st-
tins. The average rate of progression was 0.062  0.079
m2/year. Fast progression, defined as annual change in
Figure 2 MR, Viability, and Clinical Outcomes
Patients with functional mitral regurgitation (MR), which improved with coronary art
(bottom left) and less dyssynchrony (bottom right) than those that did not impro
The top one-half shows the Improvement Group had lower NYHA functional class,
 anterior papillary muscle; PPM  posterior papillary muscle. Adapted, with permitral valve area (MVA) 0.08 cm2/year, was present in uof 35 (8.6%) patients who had received statins versus 83
f 280 (29.6%) who had not received statins (p  0.008).
re- and post-procedural mitral regurgitation is associated
ith poorer outcomes after catheter balloon commissurotomy
or MS. Patients (n  876) undergoing their first catheter
alloon commissurotomy (CBC) were separated into 3 to 5
ubgroups according to mitral regurgitation (MR) grades
22). In hospital and on late follow-up (mean 4.11 years),
he incidence of composite endpoints was greater in those
ith MR (Table 1).
pen heart surgery versus CBC in MS: similar survival but
etter event-free survival with open heart surgery.
ne hundred fifty-nine patients (52  9 years of age)
pass graft surgery (CABG) (Improvement Group), had 5 or more viable segments
lure Group). Improvement Group in blue circles, Failure Group in green circles.
lity, heart failure hospital stay, and composite of mortality and hospital stay. APM
, from Likosky et al. (17).ery by
ve (Fai
morta
issionnderwent open heart surgery, and 402 (44 1 years of age)
ci
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Year in Valvular Heart Disease September 13, 2011:1197–207had CBC from 1995 to 2000 (23); their echocardiographic
scores were 9.6  1.9 and 7.3  1.4, respectively, p 
0.001. Follow-up was 106  27 months (median 109
months). At 9 years, adjusted cardiovascular death-free
survival was similar (96  2% vs. 95  2%), but adjusted
probability of clinical event-free survival was greater with
open heart surgery (94  1% vs. 80  2%; p  0.0001).
Mitral Regurgitation
Increased stress and myofibrillar degeneration in isolated
MR with LVEF >0.60. Twenty-seven patients (age 53 
12 years) with isolated severe MR and LVEF 0.66  0.05
who had no obstructive CAD, MS, or aortic valve diseases
had cardiac catheterization and were compared with 39
“normal subjects,” 40  11 years of age. Of the MR
patients, 45% were in NYHA FC I, and 55% were in FC II
(24). After mitral valve repair (MVrep), there were signifi-
ant decreases of LVEF (0.66  0.05 to 0.54  0.09, p 
0.0001) and of LV end-diastolic volume index (108 28 to
78  24, p  0.05); the increased left ventricular end-
systolic volume index was unchanged. The LV circumfer-
ential and longitudinal strain rates were reduced after
MVrep. The LV end-systolic stress/LV end-systolic volume
ndex were depressed at baseline and after MVrep when
compared with normal subjects (0.25  0.10 and 0.28 
0.25 versus 0.33  0.12, p  0.01). The LV myocardial
biopsies demonstrated myofibrillar degeneration versus con-
trol subjects (p  0.035); biopsies in control subjects were
obtained in 7 young subjects who died of noncardiac
disease. Patients with MR also showed increased xanthine
oxidase (p  0.05) and lipofuscin deposition (p  0.01).
The authors concluded that: 1) decreased strain rates and
LV wall stress/LV end-systolic volume index after MVrep
“indicate contractile dysfunction despite pre-surgical LVEF
0.60”; and 2) the “increased oxidative stress could cause
myofibrillar degeneration and lipofuscin accumulation re-
sulting in LV contractile dysfunction in MR.”
COMMENT. This is an innovative and important study. It
Effect of Pre- and Post-Procedural MR on Long-Term Outcomes AfteTable 1 Effect of Pre- and Post-Procedural MR on Long-Term O
Pre-Proce
0 1
Patients, n 484 335
Composite clinical outcome* 41% 48%
Time to clinical outcomes, yrs 4.7 0.2 3.5 0.2
Post-Proce
0 1
Patients, n 284 386
Composite clinical outcome* 35% 44%
Time to clinical outcomes, yrs 5.0 0.2 4.1 0.2
*Death, mitral valve surgery, and redo catheter balloon commissurotomy (CBC). Data from Jneid
MR  mitral regurgitation.would have been valuable to know whether the patients inNYHA FC I had findings identical or similar to those who
were in FC II.
Suboptimal reproducibility of quantitative measurements of
severity of MR. Eighteen echocardiographers from 11 ac-
ademic institutions in Israel, Japan, and the United States
evaluated the same images from 16 patients with MR (25).
The overall interobserver agreement for grading MR as
severe or not severe for jet-area-based MR grade was 0.32
(95% confidence interval [CI]: 0.1 to 0.52), for vena
contracta was 0.28 (95% CI: 0.11 to 0.45), and for proximal
isovelocity surface area was 0.37 (95% CI: 0.16 to 0.58).
Exercise echocardiography for all asymptomatic patients
with severe degenerative MR? Not yet. Sixty-one asymp-
tomatic patients with moderate-to-severe MR had rest and
bicycle exercise Doppler-echocardiography (26). Note that:
1) effective regurgitant orifice area by proximal isovelocity
surface area and Doppler provided different values; 2) the
same was also true for regurgitant volumes—mean values by
the 2 techniques differed both at rest and on exercise by an
average of 20 ml; 3) “there were no significant exercise-
induced changes in regurgitant volume”; and 4) the regur-
gitant volume and LV outflow tract stroke volume were
stated to be 77  22 ml and 81  23 ml, respectively, even
hough the LV end-diastolic volume was only 111  35 ml!
he findings on exercise are similarly discordant (see Table 2
f the authors [26]).
In-Hospital Mortality With Early SurgeryVersus Medical Therapy in Infective EndocarditisTable 2 In-Hospital Morta ity With Early SurgeryVersus Medical Therapy in Infective Endocarditis
Risk-Adjustment Method ARR, % p Value
Odds
Ratio 95% CI
Unadjusted 8.6 0.0001 0.53 0.40–0.70
Logistic regression 5.9 0.001 0.56 0.38–0.82
Propensity matched,
survivor-bias adjusted
5.9 0.001 0.55 0.31–0.96
Instrumental-variable adjusted 11.2 0.001 0.44 0.33–0.59
Ces After CBC
R Grade
2 p Value
54
68% 0.0001
2.6 0.3 0.0001
MR Grade
2 3 4 p Value
124 51 31
50% 80% 85% 0.0001
3.7 0.3 2.2 0.4 1.2 0.6 0.0001
2).r CButcom
dural M
duralAdapted, with permission, from Lalani et al. (29).
ARR  absolute risk reduction; CI  confidence interval.
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September 13, 2011:1197–207 Year in Valvular Heart DiseaseCOMMENT. This study is from an experienced center.
Nevertheless, were serious methodological issues involved in
the measurements that were made?
Improvement of moderate MR with isolated CABG for
symptomatic left main or 3-vessel CAD? Yes, in the pres-
ence of hibernating myocardium and less LV dyssynchrony.
Of 135 patients undergoing CABG, operative mortality was
4.4%, late deaths amounted to 6.2%; and 121 survived to
12-month follow-up. All patients had left main CAD or
proximal 3-vessel CAD (27). Indications for CABG were
symptoms (NYHA FC 2.5  0.9), angina in 81%, and
extent of CAD; grafted vessels averaged 3.5 1.4, 79% had
a previous myocardial infarction. Dysfunctional but viable
myocardium (hibernating myocardium) was diagnosed by a
perfusion-metabolism mismatch on single-photon emission
computed tomography, dyssynchrony by tissue Doppler
imaging (TDI). At 12-month follow-up, 57 (47%) showed
no or mild MR (“Improvement” group), and 64 (53%)
showed no improvement of MR (“failure” group); at base-
line there were no significant differences between the 2
subgroups. At follow-up the “improvement group” had
significant reductions of LV end-diastolic and end-systolic
volumes and increase of LVEF from 0.35  1.0 to 0.47 
0.09, p  0.0001. The independent predictors of improve-
ent were 5 segments with viability and absence of
yssynchrony. Of patients with viability in5 segments and
yssynchrony of 60 ms, 93% improved. In the “failure
roup” 18% and 34% of those with nonviable myocardium
nd dyssynchrony improved and 49% and 32% showed
orsening of MR, respectively (p  0.001). The clinical
utcome was significantly better in the “improved group”
Fig. 2).
ricuspid Regurgitation
igid prosthetic ring annuloplasty has the best but
nsatisfactory results for secondary tricuspid regurgitation.
rom 1990 to 2008, 2,277 patients underwent tricuspid
alve procedures at the time of aortic and mitral valve
rocedures (28). At 3 months, no tricuspid regurgitation
TR) was present in only 32% and 3/4 TR was present
n 11%. By 5 years, no TR had decreased to 22% and
/4 TR had increased to 17%. Patients with rigid ring
nnuloplasty had the least increase of 3/4 TR to 12% at
years.
COMMENT. Very good results of tricuspid valve surgery for
secondary TR are still awaited.
Infective Endocarditis
Early surgery for valve endocarditis is associated with a
better survival. NATIVE VALVE ENDOCARDITIS: A PROSPECTIVE
ULTINATIONAL STUDY OF 1,552 PATIENTS. Seven hundred
wenty patients (46%) underwent early surgery, and 832
54%) had only medical therapy (29); early surgery was
ssociated with significantly lower mortality (12.1% vs. s0.7%, p  0.001). After propensity matching and adjust-
ents for survivor bias, the absolute risk reduction was
5.9% (p  0.001), which increased to 11.2% (p 
.001) with “instrumental-variable-mortality reduction”
Table 2). In subgroup analysis, surgery conferred a survival
ith absolute risk reductions of 10.9% with propensity
atching for surgery, 17.3% in those with paravalvular
omplications, 12.9% in those with systemic emboliza-
ion, 20.1% in those with Staphylococcus aureus infection,
nd 13% in those with stroke but not those with valve
erforation or heart failure.
COMMENT. An excellent accompanying editorial dis-
cusses the difficulties of analyzing the complexity of this
problem (30).
PROSTHETIC VALVE ENDOCARDITIS. Of 133 cases of pros-
hetic valve endocarditis, 24 (18%) were early onset (60
ays after valve implantation) and 109 (82%) were late onset
2 months) after valve implantation (31).
Staphylococci were the most common organisms (72%) in
arly onset; in late onset, staphylococci and streptococcus
iridans were the cause in 29% and 19%, respectively.
Complications occurred in 16 of 24 (66.7%) of early
rosthetic valve endocarditis and in 80 of 109 (73.4%) of
ate onset.
Hospital mortality was 29.3%. There were a number of
omorbid conditions that were predictors of mortality. The
2-month survival in the medical and medical-surgical
roups was 42% and 71%, respectively (p  0.007). In the
ox regression analysis, surgical treatment was a significant
actor in better survival (odds ratio: 0.43, 95% CI: 0.24 to
.75, p  0.003). There was no significant difference in
urvival in the early and late onset groups.
llografts (homografts) and mechanical prosthesis for
ortic native valve endocarditis. One hundred thirty-
ight patients underwent AVR in 2 centers, 106 received
omografts (age 47 years, range 14 to 76 years), and 32
eceived mechanical prostheses (MP) (age 47 years, range
6 to 75 years) (32). Abscess was present in 38% of
omografts and in 8% of MP. Hospital mortality was 8%
9% with homografts and 3% for MP, p  0.25). At 15
ears, survival and recurrent endocarditis were better for MP
p  NS). Hazard ratios of structural valve deterioration
SVD) for homografts in the first 5 years, 5 to 10 years, 10
o 15 years, and 15 to 20 years were 0.23%, 0.82%, 1.0%,
nd 6.7%/patient-year, respectively. Reoperation rate was
ower for MP (7  6% vs. 24  9%, p  0.02).
ranscatheter Valve Therapy: Aortic Valve
andomized trial: transfemoral transcatheter valve ther-
py is associated with better survival than with “standard
herapy” (PARTNER [Randomized Placement of Aortic
ranscatheter Valves] trial). Of 3,105 patients with AS,
2% (358) who were considered to be “not suitable for
urgery” were randomized to transcatheter valve therapy
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Year in Valvular Heart Disease September 13, 2011:1197–207(TVT) with Sapien valve (Edwards Lifesciences, Inc.,
Irvine, California) or no prosthetic heart valve (PHV) (n 
179 in each group) (33). Patients were 83.1  8.6 years of
ge, 92% were in NYHA FC III/IV with Society of
horacic Surgeons (STS) Score of 11.2  5.8 and AVA of
.6  0.2 cm2.
At 30 days, TVT versus “standard therapy” was associated
with all-cause mortality of 5.0% versus 2.8% (p  0.41),
troke/transient ischemic attack 6.7% versus 1.7% (p 
.03), vascular complications 30.7% versus 5.0% (p  0.001),
nd major bleeding of 16.8% versus 3.9% (p  0.001). The
tatistically significant differences at 1 year are shown in
igure 3 and Table 3.
COMMENT. This is an important landmark randomized
trial. Nevertheless, certain aspects of the trial need to be
noted. First, 83.8% of patients in the “standard therapy”
group had aortic balloon valvuloplasty. This procedure was
shown in 1994 in the large National, Heart, Lung, and
Blood Institute Registry to be ineffective (34) and thereafter
was abandoned. The 2000 and 2006 guidelines give it a
Class III grade for calcified valves. To consider it as
“standard therapy” was very controversial from 2007 to
Figure 3 Randomized Trial of TAVI Versus Standard Therapy
Outcomes are better with the transcatheter valve therapy called transcatheter aort
versus standard therapy (blue). Reprinted, with permission, from Leon et al. (33).2009. It is also known to produce AR (34). The incidence
of moderate or severe transvalvular AR in the “standard
therapy” group was 16.9% versus 1.3% in the TVT group.
This is in addition to 11% incidence of paravalvular AR.
This amount of acute AR (27.9%) in the LV of severe AS
can be a problem (34). Second, 12 patients in the “standard
therapy” group had standard surgical AVR. Their 1-year
death rate was 33%, which is similar to the 31% death rate
at 1 year in the TVT group. Should the subjective classifi-
cation of “cannot undergo surgery”/“not suitable candidates
for surgery” be re-evaluated? Third, deaths from unknown
cause were assumed to be deaths from cardiovascular causes.
The numbers of such deaths in each group were not
provided and depending on the number of such deaths in
the “standard therapy” group the conclusion(s) of this trial
could be impacted. Fourth, subgroup analysis for death from
any cause was not significant in those with body mass index
25 kg/m2, LVEF 0.55, oxygen-dependent chronic ob-
tructive pulmonary disease, pulmonary hypertension, and
eripheral vascular disease.
Other issues include: 1) at 30 days the complication rate
s higher in the TVT group; 2) from Figure 3 it seems that
e implantation (TAVI) (red) in this trialic valv
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September 13, 2011:1197–207 Year in Valvular Heart Diseaseat 6 months there was no significant difference between the
2 groups for death from any cause and death from any cause or
major stroke; 3) at 1 year, several complications were much
higher in the TVT group; and 4) the multivariate predictors of
death and/or stroke were not provided.
However, this is an early stage of TVT. Improvements in
the devices, procedures, and patient selection will occur in
the ensuing years.
Transapical TVT in patients with severe AS at high risk
at a single center. One hundred seventy-five patients 79.8 
.0 years of age, with STS Score 23.5  19.4, AVA 0.57 
.22 cm2, 98.3% in NYHA FC III/IV, 5.7% in cardiogenic
hock, and LVEF 0.35 in 22.8% had transapical (TA)
VT with the Sapien valve (Edwards Lifesciences) in a
ingle center in a hybrid operating room by a team of
hysicians (cardiac surgeons, cardiologist, and anesthesiol-
gists) (35). Technical success was 100%; 30-day mortality
as 5.1% (30% in those in cardiogenic shock, and 3.6% in
he remaining patients). Survival at 1, 6, and 12 months was
4.9%, 85.5%, and 82.6%, respectively.
COMMENT. The authors emphasized the importance of
training and coordination between members of the team.
TA and transfemoral TVT for AS. In the multicenter
Canadian study of 339 patients, 168 had the transfemoral
(TF) and 177 had the TA procedure (36). The AVA was
0.63  0.17 cm2, 90.9% were NYHA FC III/IV, 69% had
CAD, estimated glomerular filtration rate 60 ml/min was
present in 56.3%, and porcelain aorta was present in 17.9%.
The STS score was 9.8  6.4%; the procedural success rate
was 93.3%. The 30-day mortality in TF and TA was 9.5%
and 11.3%, respectively. After a median follow-up of 8
TVT in Patients Who “Cannot”Undergo Surgery at 1 YearTable 3 TVT in Pati ts Who “Cannot”Undergo Surgery at 1 Year
TAVI (%) “Standard Therapy” (%) p Value
n 179 179 —
All deaths
Any cause 30.7 49.7 0.001
CV cause 19.6 41.9 0.001
Repeat hospital stay 22.3 44.1 0.001
Stroke or TIA
All 10.6 4.5 0.04
TIA 0.6 0 1.00
Stroke
Minor 2.2 0.6 0.37
Major 7.8 3.9 0.18
All deaths or major stroke 33.0 50.3 0.001
Vascular complication
All 32.4 7.3 0.001
Major 16.8 2.2 0.001
Major bleeding 22.3 11.2 0.007
Data from Leon et al. (33).
CV  cardiovascular; TAVI  transcatheter aortic valve implantation; TIA  transient ischemic
attack; TVT  transcatheter valve therapy.months, mortality was 22.1%. wThe predictors of cumulative late mortality were peri-
procedural sepsis or need for hemodynamic support, pul-
monary hypertension, chronic kidney disease, and chronic
obstructive pulmonary disease.
One hundred fifty-three patients had TVT by the TF
route, and 50 had TVT by the TA route; their STS scores
were 6.5  4.1 and 6.3  3.8, respectively (37). Patients
who had TVT by the TF and TA routes had similar NYHA
FC (3.1  0.3). Patients in the TA group were more
frequently women; had higher B-type natriuretic peptide
values and smaller AVA; and had more CAD, peripheral
arterial disease, and kinking of the descending aorta. De-
spite baseline differences, survival was similar. Some com-
plications were specific to the access site.
COMMENT. The authors emphasized that TF is the proce-
dure of first choice and TA was chosen only in patients who
had no access through diseased femoral arteries.
Cerebral emboli after TF TVT for AS. Thirty-two pa-
tients who had TVT for AS were evaluated (38); 27 (84%)
had multiple new foci of restricted diffusion on cerebral
MRI and, such foci occurred in 48% of a “control” group
who had surgical AVR. There were 1 to 19 lesions/patient;
the lesion volume was 77 mm2 (range 59 to 64 mm2), whereas
n the surgical group the lesion volume was 224 mm2 (range
111 to 338 mm2). There were no measurable impairments of
neurocognitive function and no apparent neurological events.
The MRIs at 3 months showed no change.
Thirty patients were evaluated; 20 completed the protocol
of 3 MRI images (39); 16 of 22 (72.7%) had 75 new cerebral
lesions after TVT; 3 of 30 (10%) had new neurological
findings, and 1 (3.6%) had a permanent neurological im-
pairment. The National Institutes of Health Risk Score and
serum concentration of neuron-specific enolase were not
correlated with MRI findings.
Valve prosthesis-patient mismatch after TVT for AS
with Medtronic core valve. Valve prosthesis-patient mis-
match (VP-PM) occurred in 16 of 50 patients (32%). The
VP-PM was moderate (PHV area0.85 cm2/m2) in 15 and
evere (PHV area0.65 cm2/m2) in 1 patient (40). Optimal
osition defined as optimal device depth 5 to 10 mm
ccurred in 50% of patients. The incidence of VP-PM was
6% in the optimal position and 48% in the nonoptimal
osition (p  0.015).
rosthetic Heart Valves
andomized trial: MP versus bioprostheses in patients
5 to 70 years of age. Power calculations estimated ap-
roximately 155 patients were needed in each group to have
0% power (a beta error of 20%) to detect a 10% difference
n mortality and for 2-sided alpha error of 5%.
Over an 8-year span (1995 to 2003), of 1,120 patients
ho needed AVR, 155 were randomized to MP and 158
s
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follow-up (106  28 months), there was no statistically
ignificant difference in the primary endpoint of survival
Fig. 4); however, at 12 years there were only 12 and 16
atients at risk in the BP and MP groups. In the primary
ndpoints of valve failure (SVD) and reoperation, the
ifferences in valve failure (linearized rate) in BP was 2.17%
atient year (95% CI: 1.35 to 2.95) versus 0 in MP (p 
.0001), and the differences in reoperation in BP was 2.32%
er patient year (95% CI: 1.48 to 3.18) versus MP 0.62%
er patient year (95% CI: 0.19 to 1.05) (p 0.0003). There
were no significant differences in the secondary endpoints.
COMMENT. First, the duration of follow-up in the study
was not adequate for a full appreciation of the extent of
SVD in the BP. Second, the final results are similar to the
Edinburgh (42) and Veterans Administration trials (43),
which had follow-up of 20 and 18 years, respectively, and
average follow-up was 15 years. Nevertheless, the major
finding of considerable interest and value of this trial is that
“newer” PHV (BP and MP) had no different outcomes
compared with the “older” PHV that were used in Edin-
burgh and Veterans Administration trials.
Choice of PHV in adults. An updated comprehensive
review can be seen in Rahimtoola (44).
10- to 15-year survival after AVR plus MVR in patients
<70 to >80 years. One thousand fifty-seven patients had
surgery from 1989 to 2007 in Northern New England (45).
Data are from the Social Security Administration Death
Master File. An AVR was performed in 98.1% (tissue valve
in 64.7% and mechanical in 35.4%), MVR was performed in
60.5% (of whom 51.2% had tissue valve, 48.8% had me-
chanical valve), and MVrep was performed in 39.5%. “In-
hospital” mortality for those age 70, 70 to 79, and 80
years was 11%, 18%, and 24%, respectively. Mean survival
Figure 4 Randomized Trial of MP Versus BP in Aortic Stenosis
Mechanical prostheses (MP) that were inserted were from St. Jude Medical (St. Pa
(BP) that were inserted were Carpentier Edwards (Irvine, California) porcine (n  9
Right panel: MP had a higher incidence of bleeding, BP had a higher incidence ofwas 7.3 years (Table 4).Accelerated streptokinase is not better than standard
infusion for left-sided PHV thrombosis: a randomized
trial. Of 120 patients, 60 received accelerated streptokinase
infusion (1.5 million units [MU] of streptokinase) over 1 h,
and 60 received conventional infusion (0.25 MU over 30
min) (46). In both groups streptokinase was continued at
0.1 MU/h infusion up to 72 to 96 h. There were no
statistically significant differences with regard to complete
clinical response, composite secondary outcome or major
bleeding. The success rate was low (59%) and worst in those
in NYHA FC III/IV (Table 5).
Valve Prothesis-Patient Mismatch
VP-PM determined 6 months after AVR is associated
with increased mid-term cardiac-related mortality. Six
hundred forty-five consecutive patients 72.3  7.9 years of
age had AVR between 2000 and 2007 and had indexed
nnesota) (n  107) and Carbomedics (Austin, Texas) (n  48). Bioprostheses
pericardial (n  62). Left panel: Survival was not significantly different.
failure and reoperation. Reprinted, with permission, from Stassano et al. (41).
Survival After AVRMVR/MVrep in 1,057 PatientsTable 4 Survival After AVRMVR/MVrep in 1,057 Patients
Median Survival (yrs) p Value
Whole group 7.3
Age, yrs
70 11.0 NS
70–79 5.4 NS
80 4.8 NS
CABG
Yes 5.7
No 9.5 0.001
MV surgery
MVR 6.3
MVrep 9.1
Sex
Men 9.3
Women 7.3 0.033
Data from Leavitt et al. (45).ul, Mi
3) and
valveAVR  aortic valve replacement; CABG  coronary artery bypass graft; MV  mitral valve; MVR 
mitral valve replacement; MVrep mitral valve repair.
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determined by echocardiography/Doppler (47). A VP-PM
was defined as PHV area 0.85 cm2/m2. The PHV areas
were presented for 8 different PHVs. For the 8 valve brands
for each valve size, there was a range of actual PHV sizes
that were obtained in patients (see Table 2 in their report
[47]); one such example is shown in Table 6. Follow-up
times were mean 2.66 (median 2.35, range 0.45 to 7.19)
years. A VP-PM was associated with a higher incidence of
cardiac death (Fig. 5). Predictors of cardiac death were
smaller PHV size, age, diabetes, and preoperative LVEF
0.50.
COMMENT. This is another important and valuable study of
VP-PM from the German Heart Center group in Munich.
SVD of the “stenosis type” in BP is related to VP-PM.
Five hundred sixty-four patients, 74  5 years of age, had
received 9 different brands of BP at a median follow-up of
6.1 years (maximum 16.4 years) (48). Structural valve
deterioration was diagnosed in 40 (7%), “stenosis type” was
diagnosed in 24, and “regurgitant type” was diagnosed in 16
patients. Patients with VP-PM (PHV size 0.85 cm2/m2,
 285) developed SVD that was “stenosis type” and
Outcomes With Fibrinolytic Therapyby Functional Class in Thrombosed PHVTable 5 Outcomes W th Fib inolytic Therapyby Functional Class in Thrombosed PHV
Functional Class
Accelerated
Infusion
(n  59)
Conventional
Infusion
(n  60)
Total
(n  119)
NYHA I/II
Complete clinical response 35/46 (76) 26/36 (72) 61/82 (74)
Death, major bleeding,
embolic stroke, non-CNS
embolism
8/46 (17)* 3/36 (8) 11/82 (13)
NYHA III/IV
Complete clinical response 3/13 (23) 6/24 (25) 9/37 (24)
Death, major bleeding,
embolic stroke, non-CNS
embolism
3/13 (23) 6/24 (25) 9/37 (24)
Values are n (%). *The difference was mainly due to a higher incidence of intracranial hemorrhage
(4 vs. 1) and death (3 vs. 0) in the accelerated fibrinolytic therapy group, compared with the
conventional infusion group. Data from Karthikeyan et al. (46).
CNS  central nervous system; NYHA  New York Heart Association functional class; PHV 
rosthetic heart valve.
PHV Areas Determined at 6 MonthsAfter AVR for PHV Labeled-Size #23Table 6 PHV Areas Determi ed at 6 MonthsAfter AVR for PHV Labeled-Size #23
PHV Area (cm2)
Patients (n) Mean Range
Edwards Perimount 113 1.82 1.7–1.9
Edwards Perimount Magna 38 1.82 1.7–2.0
Medtronic Mosaic 23 1.53 1.3–1.8
Sorin Mitroflow 19 1.53 1.4–1.7
Sorin Freedom Solo 7 2.00 1.6–2.3
St. Jude Epic Supra 35 1.81 1.6–2.0
St. Jude Toronto Root 6 1.60 1.4–1.8a
Data from Bleiziffer et al. (47).
AVR  aortic valve replacement; PHV  prosthetic heart valve.tarted to occur after 2 to 3 years. Patients without VP-PM
eveloped SVD of the “regurgitant type,” which started to
ccur after 9 years. Multivariate analysis showed PHV size
21, and VP-PM were predictors of increased SVD.
nticalcification treatment administered during valve prep-
Figure 5 Valve PPM and Cardiac Death
Cardiac death was greater in patients with valve prosthesis-patient mismatch
(PPM) (red) compared with those who did not have PPM (blue) in all patients (top
panel), non-obese patients (middle panel), and in those with left ventricular hyper-
trophy (LVH) (lower panel). Adapted, with permission, from Bleiziffer et al. (47).ration was a predictor of a lower incidence of SVD.
11
1
1206 Rahimtoola JACC Vol. 58, No. 12, 2011
Year in Valvular Heart Disease September 13, 2011:1197–207COMMENT. This is another excellent and careful study by
Professor Flameng. The accompanying editorial by Carpen-
tier, who introduced the term “bioprostheses” in 1969 for
glutaraldehyde-processed animal valves, is excellent and
discusses the issue of SVD (49).
Miscellaneous
Pericardial effusion after cardiac surgery with cardio-
pulmonary bypass. Of 21,416 patients operated from 1993
to 2005, 327 (1.5%) had pericardial effusion, 272 (83%) of
whom had only valve surgery. It was diagnosed at 9  6
(median 7) days, moderate or large effusion was seen at 13  6
days (50). Two hundred eighty patients (86%) had nonspe-
cific symptoms (Table 7), and 138 (42%) had cardiac
tamponade. It was recurrent in 4%. Independent risk for
effusion after valve surgery had an odds ratio of 3.7 (95% CI:
2.6 to 5.2, p  0.0001).
COMMENT. This is a necessary and very valuable study. In
much earlier times this was called the “post-pericardiotomy
syndrome.” It might occur after hospital discharge, and the
clinical presentation is nonspecific. It is important to rec-
ognize and treat this uncommon complication in a timely
fashion, because it can be life-threatening with development
of cardiac tamponade and occasionally results in “late”
development of constriction.
Reprint requests and correspondence: Dr. Shahbudin H. Ra-
himtoola, University of Southern California, 1200 North State
Street, Old General Hospital, Room 3221, Los Angeles, Califor-
nia 90033. E-mail: rahimtoo@usc.edu.
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